See the published version of this preprint at Arthritis Research & Therapy.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Qiang Wang
Zhongshan Hospital Fudan University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0466-5013
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Systemic sclerosis (SSc) or scleroderma is an intractable autoimmune disorder that affects multiple organs. The objectives were to investigate clinical correlations of serum calpain activity and high mobility group box 1 (HMGB1) levels with immunological and clinical traits.
Methods A total of 31 patients with SSc, 20 age- and gender-matched healthy control subjects (HC) and 10 patients with other connective tissue diseases (CTD) were recruited in the study. We measured serum calpain activity and HMGB1 levels and analyzed the datasets (GSE40839, GSE48149, GSE76808, GSE81292 and GSE33463) from gene expression omnibus (GEO) database to explore potential mechanism by which calpain exerts its function through bioinformatics methods.
Results Serum calpain activity was significantly increased in patients with SSc compared with those in HC and in patients with CTD and was correlated with serum HMGB1 levels, modified Rodnan skin score, erythrocyte sedimentation rate, mean platelet volume and plateletcrit. Notably, serum calpain activity and HMGB1 levels in SSc patients with interstitial lung disease (ILD) were significantly higher than that in SSc patients without ILD. Serum calpain activity and HMGB1 levels could be the independent risk factors for SSc-ILD and novel biomarkers in patients with SSc.
Conclusion This is the first study that reports increased serum calpain activity and the correlation between calpain and HMGB1 in patients with SSc or SSc-ILD. The serum calpain activity and HMGB1 levels may serve as measures of ILD in patients with SSc. Also, calpain and HMGB1 could be potentially therapeutic targets for patients with SSc or SSc-ILD in the future.
Keywords
calpain, systemic sclerosis, interstitial lung disease, calpain, HMGB1, microarray analysis
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Arthritis Research & Therapy.
No community comments so far
Editorial decision: Accept
On 20 Apr, 2020
Review #2 received
Received 14 Apr, 2020
Reviewer #2 agreed
On 06 Apr, 2020
Editor assigned
On 03 Apr, 2020
Reviewers invited
Invitations sent on 03 Apr, 2020
Reviewer #1 agreed
On 03 Apr, 2020
Review #1 received
Received 03 Apr, 2020
Submission checks complete
On 02 Apr, 2020
Editor invited
On 02 Apr, 2020
Version 1
Posted 10 Mar, 2020
No comments provided
Review #2 received
Received 24 Mar, 2020
Editorial decision: Major revision
On 24 Mar, 2020
Review #1 received
Received 22 Mar, 2020
Reviewer #2 agreed
On 10 Mar, 2020
Reviewers invited
Invitations sent on 04 Mar, 2020
Reviewer #1 agreed
On 04 Mar, 2020
First submitted
On 03 Mar, 2020
Editor assigned
On 03 Mar, 2020
Submission checks complete
On 02 Mar, 2020
Editor invited
On 02 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Arthritis Research & Therapy.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Qiang Wang
Zhongshan Hospital Fudan University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0466-5013
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Arthritis Research & Therapy.
No community comments so far
Editorial decision: Accept
On 20 Apr, 2020
Review #2 received
Received 14 Apr, 2020
Reviewer #2 agreed
On 06 Apr, 2020
Editor assigned
On 03 Apr, 2020
Reviewers invited
Invitations sent on 03 Apr, 2020
Reviewer #1 agreed
On 03 Apr, 2020
Review #1 received
Received 03 Apr, 2020
Submission checks complete
On 02 Apr, 2020
Editor invited
On 02 Apr, 2020
Version 1
Posted 10 Mar, 2020
No comments provided
Review #2 received
Received 24 Mar, 2020
Editorial decision: Major revision
On 24 Mar, 2020
Review #1 received
Received 22 Mar, 2020
Reviewer #2 agreed
On 10 Mar, 2020
Reviewers invited
Invitations sent on 04 Mar, 2020
Reviewer #1 agreed
On 04 Mar, 2020
First submitted
On 03 Mar, 2020
Editor assigned
On 03 Mar, 2020
Submission checks complete
On 02 Mar, 2020
Editor invited
On 02 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Arthritis Research & Therapy.
Background Systemic sclerosis (SSc) or scleroderma is an intractable autoimmune disorder that affects multiple organs. The objectives were to investigate clinical correlations of serum calpain activity and high mobility group box 1 (HMGB1) levels with immunological and clinical traits.
Methods A total of 31 patients with SSc, 20 age- and gender-matched healthy control subjects (HC) and 10 patients with other connective tissue diseases (CTD) were recruited in the study. We measured serum calpain activity and HMGB1 levels and analyzed the datasets (GSE40839, GSE48149, GSE76808, GSE81292 and GSE33463) from gene expression omnibus (GEO) database to explore potential mechanism by which calpain exerts its function through bioinformatics methods.
Results Serum calpain activity was significantly increased in patients with SSc compared with those in HC and in patients with CTD and was correlated with serum HMGB1 levels, modified Rodnan skin score, erythrocyte sedimentation rate, mean platelet volume and plateletcrit. Notably, serum calpain activity and HMGB1 levels in SSc patients with interstitial lung disease (ILD) were significantly higher than that in SSc patients without ILD. Serum calpain activity and HMGB1 levels could be the independent risk factors for SSc-ILD and novel biomarkers in patients with SSc.
Conclusion This is the first study that reports increased serum calpain activity and the correlation between calpain and HMGB1 in patients with SSc or SSc-ILD. The serum calpain activity and HMGB1 levels may serve as measures of ILD in patients with SSc. Also, calpain and HMGB1 could be potentially therapeutic targets for patients with SSc or SSc-ILD in the future.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...